precision compounding pharmacy semaglutide shortage ends as FDA sets deadline for compounders A secret shopper study found

WarningsFor adults only

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to treat type 2 diabetes, but clinical research has shown it produces significant weight loss in people with obesity

Richardson TG, Wang Q, Sanderson E, Mahajan A, McCarthy MI, Frayling TM, et al

Pregnant women with type 1 diabetes who had very high blood glucose levels (an HbA1c reading of 9.1 per cent or higher) were at much greater risk

Discussion This study provides a comprehensive view of how a major formulary change influenced both treatment switching patterns and overall prescribing rates for both AOM tirzepatide and AOM semaglutide